Takeaways: If approved, FILSUVEZ would become Canada’s first treatment specifically for EB-related wounds, addressing a severe unmet need for patients with chronic, painful skin breakdown and he...
Takeaways: This accelerates Italfarmaco’s commercial entry, giving it a platform to negotiate reimbursement and patient access with a distinct HDAC-inhibitor mechanism and a combinatio...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
